Phase 3 Readout~month

Phase 3 Topline: KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous

Name: Phase 3 Topline: KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous
Start: 2028-09-01

September 1, 2028

Company: Kyverna Therapeutics, Inc. (KYTX)
Drug: kyv-101
Indication: Generalized Myasthenia Gravis; Myasthenia Gravis

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous — KYTX Phase 3 Readout | BioSniper